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Objectives:
 
 Often in economic evaluations a division is
made between those studies that have a high level of ac-
curacy versus those that are easily generalized. This in-
terstudy dichotomy is often translated into prospective,
randomized controlled trials with high internal validity
and observational and modeling studies with a high
level of external validity. This article challenges this
conventional view and examines intrastudy effects on
validity.
 
Method:
 
 A review and summary of the literature was
conducted in order to assess the impact that data collec-
tion strategies will have on internal validity. Two sce-
nario models were created in order to gain a prelimi-
nary understanding of the magnitude of the problem.
 
Results:
 
 Data collection strategies have an impact on
the level of internal validity found in an economic eval-
uation. Comparisons of studies that are prospective in
nature is misleading as data collection strategy can lead
to different resource and cost estimates even when all
other relevant factors are similar. It is possible to shift
and improve the level of validity by combining different
collection methods.
 
Conclusions:
 
 Instead of viewing internal and external va-
lidity as polar opposites, validity should be considered in
terms of a continuum within a particular study. The use
of proxies to collect resource utilization estimates, the re-
liance on patient self-reported data, and the method of
collecting this type of data all impact the validity of study
results. National guidelines for the economic evaluation
of agents and devices should consider this issue in more
depth, and existing evidence rankings should be adapted
to be more appropriate to pharmacoeconomic studies.
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 cost benefit, data collection, economic evalua-
tion, methodology, proxy, resource utilization, self-report.
 
Introduction
 
Research in the discipline of pharmacoeconomics
has expanded considerably over the past decade
[1]. This expansion in the quantity of pharmaco-
economic evaluations has been accompanied, in
part, by an increased awareness of some of the
methodological issues surrounding this discipline.
The greatest interest has been in developing guide-
lines for the conduct and reporting of pharmaco-
economic evaluations.
These guidelines, for the most part, have fo-
cused on what should be included in an economic
evaluation rather than on how to conduct a phar-
macoeconomic study. For instance, the Dutch
guidelines [2], which were developed recently, pro-
vide, among other things, guidance on the appro-
priate type of study, the timing of the evaluation,
the relevance of the comparator, the use of sensi-
tivity and modeling analyses, and the reporting of
results. Although guidelines of this type are impor-
tant for providing a common framework for re-
searchers, they may provide a false sense of secu-
rity insofar as design issues are not adequately
addressed.
The internal validity of a particular study, de-
fined as the true reflection of treatment on the
outcome of interest, is dependent critically on the
design chosen. Researchers and individuals that
evaluate pharmacoeconomic studies recognize the
trade-off between choosing a prospective evalua-
tion over a retrospective one: The estimates derived
from a prospective evaluation in most cases will
have a higher degree of precision compared to a
retrospective study [3]. Unfortunately, there has
been relatively little research conducted into how
within a prospective or a retrospective study inter-
nal validity can be improved or compromised due
to the selection of the method or mode of data col-
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lection. Such issues in validity and bias may be
considerable across studies.
This article examines this issue in depth, and in
particular for the case of prospective, clinical, trial-
based evaluations. Although there are several meth-
ods for collecting data in a pharmacoeconomic
trial, we concentrate on three main areas: the use
of patient self-reported data, the use of surrogate
respondents to collect resource utilization data,
and the mode of administration for questionnaires.
We briefly describe, in turn, why and how these
methods are used and the relative merits and weak-
nesses of the techniques. We then describe how
these techniques lead to different levels of internal
validity within a trial and how switching between
techniques may alter the level of validity. We con-
clude with a discussion on the types of studies that
are required and how guidelines may need to be al-
tered in order to ensure that the most accurate re-
sults are achieved. We focus on the internal and
external validity of these data collection processes
and on the measurement validity, defined as the
ability of a measure to assess what it was designed
to assess.
 
Patient Recall and Self-Reported Data
 
Researchers who conduct pharmacoeconomic eval-
uations often use face-to-face, telephone, or self-
administered questionnaires to obtain information
on health care resource utilization and indirect
costs. This occurs when access to hospital records
or claims data is limited or the patient is the only
practical source of information (e.g., work loss
and disability days). This self-reported informa-
tion is then used in evaluation exercises of health
service use. This information, in many instances,
may provide the bulk of resource use estimates in
any particular evaluation. As such it is crucial to
evaluate the validity of these estimates. For in-
stance, there will necessarily be some error present
when using self-reported data, and when overre-
porting and underreporting do not cancel each
other out, estimates of actual resource use will be
incorrect.
A comprehensive review was undertaken to de-
termine the potential impact that patient self-
reported data has on the internal validity of esti-
mates [4,5]. This review noted that there were
several areas that researchers should consider be-
fore employing self-reported data in an economic
evaluation:
• the length of the recall period or the recency of
the event
• the salience of the episode, both in terms of its
psychological impact on the patient and the
length of the episode
• the level of social desirability attached to an
episode
• the tendency to recall recurring events as a
group
• the demographic characteristics of patients
Although each study is unique in terms of de-
mographic characteristics, the condition evaluated
(chronic vs. acute), and the therapies examined,
several common problems have emerged. Table 1
provides a list of these issues as well as the antici-
pated impact on resource utilization estimates. For
example, a patient responder may recall an inci-
dence of resource use; however, the actual resource
consumption occurred outside of the study period.
Backward telescoping occurs when the resource es-
timate actually occurred within the reference pe-
riod, but the respondent recalls it as occurring before
the reference period. Forward telescoping occurs
when resource use that occurred before the refer-
ence period is incorrectly remembered as occurring
within the reference period.
The perceived desirability of the event also im-
pacts the accuracy of results. Events or behaviors
that are seen as desirable may be overreported
(such as income). Conversely, if the behavior or
the event is viewed as undesirable there may be a
tendency to under-report the associated resource
use due to embarrassment or a lack of willingness
to be candid with an interviewer.
Another problem that arises is that patients,
particularly in chronic conditions, may form a ge-
 
Table 1
 
Issues in the use of patient self-reported data
 
Problem Issue Typical impact on results
Length of recall period Backward telescoping False negative
Forward telescoping False positive
Socially desirable event Acquiescence bias/self-presentation bias False positive
Socially undesirable event Interviewer effect False negative
Frequency of consultation Generic memory False negative
Salience of event Difficulties in temporal sequencing of low-salience events False negative
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neric memory of their health care resource use.
That is, patients may recall events as a group and
have difficulty in recalling particular instances.
This problem will be particularly acute for repeat
visits of a chronic nature that have low salience or
impact on patients’ lives (such as general practitio-
ner, or GP, consultations).
Demographic characteristics also play an im-
portant role in determining the internal validity of
estimates based on patient self-reported data. It
has been noted that there is a tendency for certain
factors to influence the ability or the willingness of
a patient to recall a particular health care episode
[4]. Although there has been a lack of consistency
in the findings of studies, on balance the following
characteristics are likely to be associated with un-
derreporting of resource use: older age, single mari-
tal status, low income, and low education level [6–9].
In general, any study will have a mix of false
positives (overreporting) and false negatives (under-
reporting); however, the use of self-reported data
will in most instances lead to a net underreporting
of resource utilization in a particular study.
The implications of this for study design are
considerable. For example, studies that examine
inpatient hospital resource use for an acute condi-
tion in a middle-aged population may be able to
use a recall period of approximately 6 months.
However, a study that wished to examine physi-
cian consultations in a chronic condition in an el-
derly population would need to consider using a
much shorter recall period. This is necessitated by
the fact that the GP consultations have lower sa-
lience than hospitalizations, chronic conditions
face the pitfall of generic memory, and elderly pa-
tients are more likely to be cognitively challenged.
Further problems arise if researchers desire to
disaggregate results by resource category. In this
case, each resource category compared between
groups will have problems. For instance, GP visits
may be underreported, whereas inpatient stays
may conceivably be overreported. Although the
underreporting and overreporting will partially
cancel each other out, if the researcher chooses to
focus on one particular category of resource con-
sumption where there is misreporting, a mislead-
ing picture of cost differences may occur.
 
Proxies
 
It is generally agreed that in outcomes research pa-
tients are the most appropriate source of informa-
tion on their resource use. Patients have direct ex-
perience with health care providers and are more
likely to remember, in detail, health care encoun-
ters. However, in some instances it is necessary to
search for a valid alternative source of patients’ re-
source use when the patient is cognitively im-
paired due to declining health or is too young to
provide direct estimates. In addition, under condi-
tions where a patient may be able to complete a
questionnaire, but due to ill health or a lack of
willingness (e.g., terminal diseases or excess re-
spondent burden) does not comply, the use of a
proxy respondent may lead to more complete case
records.
There are various techniques for handling miss-
ing data, but as a general proposition it is prefera-
ble to have an actual estimate from a valid data
source. The problem of missing data is substantial,
particularly for elderly patients. A large survey of
the general population in the United States [10] re-
vealed that 15% of hospitalizations occurred in
5% of the sample that were nonrespondents to the
survey. A study conducted in Baltimore of elderly
hip fracture patients [11] revealed that of 858 pa-
tients identified, 51% could not be interviewed
due to cognitive impairment, illness, refusal, or
death. Thus, gaining the cooperation of proxies is
likely to increase the sample size for a study and
reduce the number of missing observations.
Although the use of proxies may increase the
sample size of a study and reduce the number of
missing items, their use in pharmacoeconomic
studies leads to a number of methodological prob-
lems. The primary issue is the accuracy of resource
estimates derived from proxies. Proxies may not
be as sensitive to patient resource use as the pa-
tient and they may fail to detect an episode of
care. In addition, they may identify resource use
when in fact it did not occur. Thus, conceptually,
pharmacoeconomic studies that use proxies to col-
lect estimates of resource use will have some level
of error associated with them as exact agreement
between patient and proxy reports will occur only
in limited circumstances (e.g., when the proxy
provides a report of an acute episode of care that
occurred recently).
Researchers in the field of quality of life and ep-
idemiology [12,13] have theorized that the rela-
tionship between the patient and the proxy, living
arrangements, the time spent between the patient
and the proxy, and how directly observable the ac-
tivity is will have an impact on the accuracy of es-
timates between patients and proxies [14]. A strong
relationship between patients and proxies, as of-
ten found in spouses, will encourage greater agree-
ment. In addition, at least for quality-of-life assess-
ments, if the proxy and the patient live and spend
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a substantial amount of time together the level of
agreement will also be high. Activities that are di-
rectly observable by the surrogate, as many re-
source use items are, will likely have a high level of
agreement when compared to the self-responder.
The level of agreement for pharmacoeconomic
evaluations will not be perfect if studies in the
field of quality-of-life research are a guide. A re-
view of this issue in the quality of life of patients
with chronic diseases found that providers might
overestimate patients’ feelings of anxiety and de-
pression and underestimate impairment in func-
tional status [15]. Of course, pharmacoeconomic
research is different from quality-of-life research,
and it is possible that when agreement on quality-
of-life scores between provider proxies and pa-
tients is low, it might be quite high for resource
use, because this is directly observable (to some
extent) for providers.
The level of agreement between proxies and pa-
tients has not been well established. Recently a re-
view of the literature [16] was conducted that
found that when comparisons were made, proxies
suffer from the same issues of patient recall and
reporting as shown above. Although the use of
proxies has been relatively well researched in the
fields of epidemiology and quality of life, there is a
dearth of evidence available concerning the impact
of surrogate respondents on resource utilization
estimates. Even answering the seemingly simple
question of the direction of the error is problem-
atic. Although the evidence suggests underreport-
ing to be more likely, the studies reviewed found
instances of overreporting as well, particularly in
the area of hospital days. In general, it seems likely
that the salience of any particular event is less for
the proxy than for a self-responder. This will lead
to a further underreporting of resource use over
that which would have been found had the infor-
mation been based solely on patient self-reported
data.
 
Collection Modes
 
There are several factors that must be considered
when selecting a data collection mode for a phar-
macoeconomic trial. Often, the primary consider-
ation is the time and expense associated with a
particular mode. Face-to-face interviews are con-
sidered the most expensive and time consuming to
conduct, while telephone interviews and mail sur-
veys are relatively less expensive.
Beyond time and cost, the mode selected has
important implications for study validity [17]. For
instance, noncoverage and nonresponse bias are
highest for mail (self-administered) questionnaires
and for telephone interviews. However, they tend
to be better than in-person interviews because they
minimize interviewer effects. Mail surveys also
have an advantage in that they allow respondents
time to reflect on their answers compared to top-
of-the-head responses typical in telephone and in-
person interviews. Two disadvantages of mail sur-
veys are that they do not allow for probing by in-
terviewers and they cannot be used in populations
with visual impairment or low literacy.
The level of accuracy obtained from different
data collection modes has not been well investi-
gated for items of health care resource utilization.
Weeks et al. [18] validated information obtained
from in-person interviews and telephone interviews
with medical records and found only minor differ-
ences in the two modes in terms of the accuracy of
the data. The accuracy of ambulatory care visits was
higher for telephone (56.3% exact or partial agree-
ment) compared to in-person interviews (46%). A
slightly higher percentage of agreement on hospital
stay and condition was achieved for the telephone
(53.2%) compared to in-person interviews (49.3%).
Yaffee et al. [7] also found no consistent differ-
ence in reporting accuracy among different survey
strategies over a 6-month period: monthly tele-
phone, bimonthly telephone, monthly telephone–
in-person, and bimonthly in-person. All of the
strategies suffered in terms of accuracy when com-
pared to validated data. However, the in-person
data collection mode did slightly better in one lo-
cation of the survey for reporting of utilization
and charges.
An important shortcoming of the studies re-
ported above is that they only report the level of
accuracy, not the level of under- or overreporting.
An early study conducted by the US Department
of Health, Education and Welfare [19] examined
this issue, comparing two modes to the medical
record criterion, the standard health interview sur-
vey, and an altered health interview survey with a
mail follow-up. This study found that percentage
of underreporting fell with follow-up. For self-
responders, episodes of hospitalization were un-
derreported by 10% and proxies for adults under-
reported by 21%. For respondents who received a
mail follow-up the percentage of underreporting
fell to 6% for both proxies and self-reporters.
It has been suggested that face-to-face and tele-
phone modes are likely to be comparable in terms
of validity [20]. Postal surveys are likely to yield a
lower level of validity. Mixed modes of data col-
lection in some instances may provide the highest
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level of validity. For example, the use of regularly
scheduled telephone interviews to supplement the
collection of patient diary information may reduce
recall bias when a patient completes the entire di-
ary a week before his/her 6-month protocol visit.
The telephone interview will collect data for the
noncompliers at a more appropriate interval. Al-
ternatively, a postal copy could be sent to a pa-
tient, followed by a telephone interview for data
collection. This would allow the patient time to
reflect on the questions prior to the telephone in-
terview, which is beneficial because the telephone
interview typically requires patients to provide
top-of-the-head responses without adequate re-
flection and processing time.
 
Compromised Validity and Bias
 
The information provided in the previous section
represents the impact that the use of patient recall,
proxies, and data collection strategies may have
on time, expense, accuracy, and generalizability.
These discussions demonstrate that even within a
prospective study, different levels of internal valid-
ity are achieved depending on the data collection
strategy chosen. The use of patient self-reported
data lowers the level of internal validity compared
to a source-documented case report form (CRF).
Consistent with the findings reported in the litera-
ture, the use of proxy reports further lowers the
validity of estimates. In terms of the mode se-
lected, a mixed-mode approach may yield a higher
level of validity compared to the self-reported data
and proxies, but it does so by increasing the finan-
cial cost of the study.
As a theoretical proposition, it is interesting to
note that the internal validity of a prospective
study may fall so far, due to the combined effects
of recall problems and mode selection, that a ret-
rospective study may in fact achieve a higher level
of internal validity. It should be noted that the ap-
parent advantage in this case is not due to any in-
herent benefit of using a retrospective study, but
to the lack of accurate data in a prospective trial.
The extent to which this may happen may be de-
pendent on the interaction of a number of factors.
Figure 1 represents the relationship between re-
trieval problems and internal validity.
Given that internal validity or the accuracy of
the estimates is impacted by the data collection
methods chosen in a particular study, it is worth-
while to investigate the implications of this on de-
cision making. Under most circumstances, within
a standard piggyback trial, the problem will be
with data accuracy rather than bias. Here bias is
defined as misidentifying the pharmacoeconomic
profile of a particular agent so that one agent is er-
roneously favored over another one, when in some
cases the reverse situation is true. Assuming that
the trial is adequately powered, has relatively strict
inclusion and exclusion criteria, and is random-
ized, demographic characteristics of patients should
be similar at baseline between groups. This will, in
most cases, control for demographic factors that
may impact recall, proxy response, and the ability
to complete a particular data collection mode. If
differences in baseline factors occur, one will need
to examine their impact on resource utilization re-
porting. Thus, the net effect will be to inaccurately
estimate resource use by a similar (although not
exact) proportion. In this case, if one agent is shown
to dominate another agent, researchers may feel
confident that the correct agent was identified
even though the cost estimate is probably under-
stated. However, under conditions that are argu-
ably unlikely to arise, it is possible that bias may
appear when two interventions are compared within
a trial.
 
Scenario I.
 
Consider the scenario outlined in Ta-
ble 2, where a surgical intervention (Intervention A)
is compared to a strategy of watchful waiting (In-
tervention B) in the context of a Phase III piggyback
study. The following assumptions have been made:
• The cost of the surgical intervention is sub-
stantially higher than the cost of the strategy of
watchful waiting.
• The cost of follow-up care for the strategy of
watchful waiting is substantially higher than
the cost associated with the surgical care.
Figure 1 Relationship between retrieval and internal valid-
ity. CRF, case report form.
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• The trial is sufficiently large and participants
are randomized to treatment (although obvi-
ously not blinded). Due to this, the percentage
of underreporting of resource use is nearly
identical (in this case equal) between trial arms,
assumed at 50% in this example.
The results, reported as total costs, show that
the watchful waiting strategy is preferred ($5,600
vs. $6,250). However, if the true data were avail-
able, then Intervention A would be revealed as
having the better cost profile ($6,500 vs. $10,600).
Thus, in this situation, bias has occurred within a
clinical trial.
DATA 3.5 (TreeAge Software, Inc., Williams-
town, MA) was used to generate a univariate sensi-
tivity analysis and threshold value to test the above
scenario. When the cost of Intervention A was re-
duced to between $700 and $1200 (potentially a
more realistic scenario) the expected value for In-
tervention A fell to $1450 (at the upper end of the
range). In this case, Therapy A would be identified
correctly as having the lower costs and the prob-
lem of bias would not occur. The threshold analy-
sis, on a broader range of $0 to $7000, indicated
bias becomes an issue at $5350. When the cost of
Intervention A is greater than $5350, it would be
shown as the more expensive strategy, when in
fact it was not. In other words, assuming the fol-
low-up costs reported, Intervention A has to be
$4650 more expensive than B in order for there to
be a problem with bias.
Although the percentage of underreporting is
equal between arms, this assumption should be
questioned in practice when there is such a large
difference in the cost of follow-up care. The higher
cost of follow-up care for the watchful waiting
strategy suggests more inpatient consultations,
which are more likely to be recalled. In this situa-
tion, the reported values for the watchful waiting
strategy would actually be much higher (and closer
to the true value) than is represented here. Re-
searchers should be sure to examine their data for
potential fallacies, such as this one. A threshold
analysis here indicates that if the follow-up care
reported for Intervention B were greater than
$5650 (which would reflect more accurate report-
ing), then Intervention A would have an expected
value lower than Intervention B. This would be
the correct identification of the relative cost pro-
files of the interventions.
Given the extreme nature of the above scenario,
users, researchers, and reviewers should have some
confidence that pharmacoeconomic studies can be
a valuable tool in the identification of preferred
therapies, although the actual impact on costs will
remain somewhat illusionary. In other words, the
more cost-effective treatment will likely be selected,
but the magnitude of cost differences will be im-
precise. Although the problem of bias is unlikely
to arise within a study, it may occur when two
studies are compared. To illustrate the issue, Sce-
nario II has been developed.
 
Scenario II.
 
Pharmaceutical Company A devel-
ops Drug A for the treatment of Condition X. As
part of its clinical development activities, it con-
ducts piggyback studies as part of two Phase III
pivotal trials that compare Drug A to usual care in
terms of resource use.
Pharmaceutical Company B develops Drug B for
the treatment of Condition X. As part of its clini-
cal development activities it conducts piggyback
studies on two Phase III pivotal trials that com-
pare Drug B to usual care in terms of resource use.
The trials conducted by both Companies A and
B are identical in every aspect (e.g., inclusion/
exclusion criteria, resources collected, end points,
and time frame). The only difference in the proto-
col is in the data collection strategy used to collect
information on resource use.
Company A decides to collect resource utiliza-
tion based on CRFs with source documentation
based on all medical records for the inpatient
baseline hospitalization and rehospitalization to
Month 12. Follow-up visits are recorded for a fur-
ther 12 months by an in-person interviewer. To
ensure that accurate results are achieved, a mail
survey is sent to respondents to check and alter
any incorrect answers.
Company B decides to collect resource utiliza-
tion based on patient self-reports at Month 12. An
 
Table 2
 
Bias within a piggyback trial
 
Cost of 
Intervention A ($)
Cost of follow-up 
care (actual) ($)
Cost of follow-up
care (reported) ($)
Total cost 
(actual) ($)
Total cost
(reported) ($)
Intervention A 6,000 500 250 6,500 6,250
Intervention B 600 10,000 5,000 10,600 5,600
 
Source: The information provided in this table was provided to the authors as an illustration at the 1999 summer meeting of the HESG.
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in-person interview is conducted 12 months later
to collect information on additional items of re-
source use.
Assume that the data in Table 3 are derived.
The example provided in Table 3 is meant to be il-
lustrative, rather than a definitive statement as to
the magnitude of the problem. As the table dem-
onstrates, the presence of recall and mode effects
are more prevalent in the second drug study con-
ducted by Pharmaceutical Company B. In the ab-
sence of any recognition of the impact of data col-
lection strategies on internal validity, erroneous
conclusions might be reached. Under the stylized
situation above, the trials are identical in all seem-
ingly important aspects. Thus, it could be argued
that it is appropriate to bridge the results of the
study, so that Drug A can be compared to Drug B.
If this were the case, then the conclusion would be
reached that Drug B has a more favorable profile
compared to Drug A. However, if figures were
available on the true cost of the treatment (Table
3, column 2), Drug A clearly has the preferred
profile. The only marker, in terms of study results,
that there is a bias issue is the underestimate of
costs in the usual care arm for the second study
compared to the first. Again, researchers should
look to identify these signs in an effort to identify
problematic results.
 
Conclusion
 
As the number of economic evaluations has in-
creased it is important to expand our understand-
ing of data collection issues to the impact of study
validity. The quantity of economic evaluations has
not been matched by an equivalent rise in the qual-
ity of evaluations. The first step in ensuring the
quality of pharmacoeconomic research is through
good study design. The above discussion has high-
lighted areas where there may be shortcomings in
the design of economic evaluations. However, our
knowledge about the direction and magnitude of
recall, proxy, and mode effects is limited. Research-
ers should evaluate a priori the anticipated effects
of different modes and methods of data collection.
This will allow the appropriate development of
a data collection strategy. For example, if a study
is to be conducted in a terminal disorder, the re-
searcher can anticipate nonresponse as the patient
approaches death. To avoid loss of data, they may
wish to employ proxy reporting. Since it is known
that proxy responses are not that accurate, the re-
searcher may wish to collect information from
both the proxy and the patient throughout the
study. This way, when the patient will not or can-
not complete a questionnaire, the proxy responses
could be adjusted for the lack of agreement.
This work has suggested that there may be a
considerable gap between obtaining data and de-
riving a correct answer to any question in pharma-
coeconomic research. This article has highlighted
the fact that internal validity may suffer substan-
tially in the face of different data collection meth-
ods. As internal validity is a necessary precursor to
external validity, it is likely that studies believed to
have a high level of external validity in fact do
not, even when such evaluations are conducted
under naturalistic conditions. Given the lack of at-
tention placed on the importance of data collec-
tion methods it appears that an assumption has
been made by some researchers that data col-
lected—regardless of source or collection meth-
ods—yield similar levels of quality. Further re-
search is required, in particular for proxy and
mode effects, to determine the impact on the inter-
nal validity of results.
Validation studies are necessary in order to en-
dorse the various techniques in the field of phar-
macoeconomics. Validation studies have been a
fixture of quality-of-life research and epidemiol-
ogy for decades. However, there have been rela-
tively few of these types of studies conducted in
pharmacoeconomics. Prospective validation stud-
ies, which compare the different techniques in
terms of agreement and error, are necessary so
that researchers can evaluate the impact that the
data collection methodology and chosen mode
have on the results of economic evaluations. This
is not an easy task, as some pharmacoeconomic
 
Table 3
 
Bias between studies: Scenario for mode and recall effect
 
True cost ($) Recall effect Proxy effect Mode (and recall) effect Estimated cost ($)
Drug A 15,000 0 NA 0.06 14,100
Usual care A 15,500 0 NA 0.06 14,570
Usual care B 16,500 0.10 NA 0.10 13,200
Drug B 16,000 0.10 NA 0.10 12,800
 
Recall and mode effect based on US Department of Health, Education and Welfare [19].
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studies will require several validation studies. For
instance, validation studies that are conducted should
be designed so as to decompose the mode effect
from the recall effect. Where under- and overre-
porting have been reported in patient recall stud-
ies it is not always possible to discriminate be-
tween mode and recall effect (Fig. 1).
The creation of preliminary guidelines may also
prove useful. Guideline development for economic
evaluations has become stagnant. The recent Dutch
guidelines offer no improvement over guidelines
developed for Ontario in 1994. In the intervening
5 years considerable research has been conducted
into the methodology of economic evaluations,
yet additional information is excluded from these
guidelines. Although it is apparent that adherence
to guidelines is often irregular, they are often most
useful to individuals least familiar with economic
evaluations. In terms of incorporating information
on data collection strategies, it would be prema-
ture to include information of proxy and mode ef-
fects; however, the issue of patient recall is more
straightforward and it would be possible, at the
least, to give guidance as to the issues involved in
using alternative strategies.
Currently, there is no objective way to assess
the overall validity of estimates derived from phar-
macoeconomic trials. Cook et al. [21] proposed an
evidence-ranking system that considered the de-
sign of a trial in determining the strength of rec-
ommendation that should be made from a particu-
lar trial (Table 4). This suggests that prospective,
randomized trials provide the highest-quality evi-
dence, whereas information derived from case
studies are anecdotal in nature and may not be
nearly as useful in informing decision making. As
noted above problems arise in pharmacoeconomic
studies that suggest that existing evidence rank-
ings are likely to be of little use in pharmacoeco-
nomic research. For instance, Level I in the typol-
ogy of Cook et al. [21], includes large randomized
trials with clear-cut results. Studies that fall into
this category receive a high level of recommenda-
tion. This would include many Phase III trials of
drugs used for registration purposes. However,
even though the clinical aspects of the trial may re-
ceive an A recommendation, there is little reason
to assume that the pharmacoeconomic results ex-
pressed as part of a piggyback deserve such a high
recommendation. The reason for this is that a pig-
gyback trial resorts to retrospective data collection
within the prospective trial and may include proxy
and mode effects.
Evidence-ranking systems developed recently are
more comprehensive, yet they are still insufficient
for pharmacoeconomic purposes (Table 5). Addi-
tional work needs to be directed at developing evi-
dence rankings that are applicable to pharmaco-
economic studies. Even though a considerable
amount of pharmacoeconomic research is con-
ducted alongside clinical trials, the nature of eco-
 
Table 4
 
Levels of evidence for therapy
 
Level Type of trial Grade
I Randomized trial with low errors A
II Randomized trials with high errors B
III Nonrandomized concurrent cohort studies C
IV Nonrandomized historical cohort studies C
V Case series C
 
Table 5
 
Hierarchy of evidence
 
Experimental
I Well-designed randomized controlled trials
Other types of trials
II-1a Well-designed controlled trial with pseudo-randomization
II-1b Well-designed controlled trials with no randomization
Observational studies
II-2a Well-designed cohort (prospective study) with concurrent controls
II-2b Well-designed cohort (prospective study) with historical controls
II-2c Well-designed cohort (retrospective study) with concurrent controls
II-3 Well-designed epidemiological case control (retrospective) study
III Large differences from comparisons between times and/or places with and without intervention (in some 
circumstances these may be equivalent to level II or I)
Expert opinion
IV Opinions of respected authorities based on clinical experience; descriptive studies and reports of expert committees
 
Source: NHS Center for Review and Dissemination (1996) cited in Rittenhouse B. Use of Models in Economic Evaluations of Medicines and Other Health Technol-
ogies. London: Office of Health Economics, 1996.
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nomic evaluations is such that the strength of any
recommendation is based on many more factors.
Evidence rankings that are based on principles
rooted in epidemiology will prove more useful
than rankings developed for clinical research. The
NHS Center for Review and Dissemination has
proposed a hierarchy of evidence that may provide
a framework for pharmacoeconomic research. Ta-
ble 5 shows that additional categories are appro-
priate for these ranking systems.
Table 3 suggests that there are also implications
for reporting pharmacoeconomic information in
league tables. League tables have been developed
so that researchers may place their findings in a
broader context and make informed decisions about
the allocation of health care resources. The useful-
ness of league tables was reviewed several years
ago [22] and it was revealed that decision-makers
should exercise caution when interpreting them
because of differences in discount rates, the method
for estimating utility values, the range of costs and
consequences considered, and the choice of com-
parators between studies. Because data collection
procedures are likely to differ between studies,
league tables will also contain misordering of con-
ditions and therapies due to the method selected.
Inasmuch as inappropriate order occurs on league
tables, therapies may be adopted upon erroneous
data. Budgetary impact analyses of these therapies
will also be misleading in magnitude. Thus, in the
long run, this will cause an unexpected burden on
the health system. Although this effect is likely to
be small, for poorly designed trials and at certain
thresholds the inappropriate selection of data col-
lection methods may have important implications
for drug adoption and reimbursement.
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